Carregant...
4CPS-086 Proposal to darunavir (drv) the least trough plasma level (tpl) cut-off to estimate plasma hiv viral load (hvl) equal or less than 20 copies/ml
BACKGROUND: Darunavir (DRV) is a high genetic barrier protease inhibitor, which when it is combined with a booster drug such as ritonavir or cobicistat, has shown high effectiveness in wild types such as resistant strains of HIV. The lack of conclusive population studies has determined a consensual...
Guardat en:
| Publicat a: | Eur J Hosp Pharm |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Group
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535845/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.177 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|